We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CEL Celadon Pharmaceuticals Plc

2.50 (2.5%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  2.50 2.5% 102.50 2,440 08:00:00
Bid Price Offer Price High Price Low Price Open Price
100.00 105.00 102.50 102.50 102.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 24k -17.01M -0.2722 -3.77 64.03M
Last Trade Time Trade Type Trade Size Trade Price Currency
10:47:32 O 1 105.00 GBX

Celadon Pharmaceuticals (CEL) Latest News

Celadon Pharmaceuticals (CEL) Discussions and Chat

Celadon Pharmaceuticals Forums and Chat

Date Time Title Posts
16/11/202318:27Celadon Pharmaceuticals Plc51
19/3/202316:34Caparo Energy23
10/10/200917:30Celsis - Sales and Profits grow1,036
06/6/200815:22Chris Evans - Biotech Guru1,401
04/7/200708:03Celsis - Bios that make money23

Add a New Thread

Celadon Pharmaceuticals (CEL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Celadon Pharmaceuticals (CEL) Top Chat Posts

Top Posts
Posted at 04/12/2023 08:20 by Celadon Pharmaceuticals Daily Update
Celadon Pharmaceuticals Plc is listed in the Investment Advice sector of the London Stock Exchange with ticker CEL. The last closing price for Celadon Pharmaceuticals was 100p.
Celadon Pharmaceuticals currently has 62,469,773 shares in issue. The market capitalisation of Celadon Pharmaceuticals is £64,031,517.
Celadon Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.77.
This morning CEL shares opened at 102.50p
Posted at 16/11/2023 16:18 by czar
Take a look back at GW Pharma they were a penny stock on AIM that followed the same path as Celadon and sold for $7.2b $220 a share. CEL will emulate GW, maybe not $220 a share but many many times the current price IMHO.
Posted at 16/11/2023 10:04 by jaknife
Ahhh Luke Warm,

It's not a particularly great name to be associated with. I'm expecting a standard equity fund raise at some point, whereupon the convertible will be converted. I assume that GIS are already selling short.


"There are a lot of small caps with absurd valuations and Celadon should be many times the current price IMHO."

The problem is that CEL's valuation is absurdly high rather than absurdly low.

At 102.5p it's a £64m market cap but the interims:

show a company with just £3m of net equity of which £1.6m of that is cash and it burnt £3.5m of cash in the last six months!

It's an obvious dog!

Posted at 16/11/2023 07:47 by czar
Note the bid for Hotel Chocolat, yesterday its worth £189m, today £534m. There are a lot of small caps with absurd valuations and Celadon should be many times the current price IMHO.
Posted at 16/11/2023 07:33 by ahhh luke warm
London, 16 November 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, announces that it has entered into a contract for the commercial supply of its pharmaceutical-grade cannabis product with a leading European medicinal cannabis company.The contract has the potential to generate revenue to Celadon of up to GBP26 million of product (GBP8.7 million annually) over the three year term, with the first delivery anticipated in H2 2024. The two parties retain the option to extend the contract for a further two years by mutual agreement.This latest sales contract follows the two previous UK contracts announced in May and September 2023 respectively.
Posted at 05/9/2023 18:07 by jaknife
No comment on todays RNS?

Am I the only person interested in CEL?

Posted at 05/6/2023 11:22 by jaknife
Any comments on today's finals?

* Pitifully small revenue of just £24k & cost of sales of £90k
* Hence every £1,000 of product sold cost the company £3,750 to make!
* material operating costs giving an overall operating loss of £5.4m!
* Other astronomical costs making a total loss before tax of £18.1m!
* Cash as at 31 Dec 2022 of £5.1m
* But cash as at 31 May 2023 of just £1.8m so cash burn in the first five months of the year is £3.3m, equal to £0.66m a month
* net assets at year-end of just £7.0m, which must be c. £3.7m at 31 May

* All of this for a bargain market cap of £100m - more than 25 times net assets
* Alternatively put, the share price needs to fall 96% to get close to net assets

Is Celadon the easiest and most obvious short on AIM?

Posted at 11/4/2023 07:20 by czar
saint I think the point with this stock is it should never have gone below the placing price of 165p. This all came about because Cannacord reversed Celadon into a shell which was established to take a software business in. As soon as they listed the shareholders in the shell sold out and destroyed the share price. Celadon have made very significant progress and are now the only UK based company with the licence to grow and sell medical grade cannabis in the UK and one of only 11 worldwide. The potential is huge. The James Short interview is worth a listen if you haven't heard it.
Posted at 16/3/2023 10:01 by czar
There clearly are very few private investors involved in CEL, several are using this thread to promote other stocks but none of these have the Home Office Licence. The truth is only a handful of companies worldwide can supply medical-grade cannabis to the pharmaceutical industry, this is an extremely valuable Company IMHO. Celadon will almost certainly receive a take over approach, its a question of WHEN not IF. The big question is at what level a bid will come in at and what would the management accept? GW Pharma gives a great clue as to the sort of number we can expect.

" -- Receipt of updated Home Office licence enables Celadon to commence the commercial supply of its GMP pharmaceutical cannabis product

-- GMP registration is understood to be the first such registration of a UK pharmaceutical facility for high THC cannabis active pharmaceutical ingredient ("API") since the legalisation of medical cannabis in 2018

-- GMP registration and a Home Office licence are required in order to sell high-THC medicinal cannabis in the UK

-- Celadon becomes one of a small number of companies globally with the capability to produce an EU-GMP grade high-THC cannabinoid API"
Posted at 14/3/2023 15:42 by oakridge
Some thoughts on CEL and HELD (from the HELD thread) below.

(Don't forget CEL possibly need a cash injection so don't get greedy on the spike!)

Oakridge14 Mar '23 - 15:20 - 480 of 481 Edit
0 1 0

News out at CEL.

Great news for the cannabis space.

What we can say is that CEL, or, those involved in the work around this RNS = a leaky ship! Including that big volume spike / buy a few weeks ago. Naughty!

Oakridge14 Mar '23 - 15:40 - 481 of 481 Edit
0 0 0

It's important to watch the reaction at CEL, and particularly the rocket that has been put under the companies share price over recent days.

The home office has now extended their license so that they can enter into commercial (non research) agreements to sell a high THC content product to third parties and are the first UK based pharmaceutical facility / cultivators in the UK to do this.

They say:

"Within the UK, patients prescribed medicinal cannabis are reliant on imported product, often facing lengthy delays and high costs, and by becoming a UK-based producer, Celadon is in a prime position to alleviate the issues currently faced by patients."

Well, it's going to be interesting to see what price-point CEL can come in at and maintain. They've already announced that expansion into their second growing room had to delayed this year by spiralling costs we have all grown so familiar with.

Their facilities are, I think, only around 10% of HELD's entire license. I'll check on that.

So, whilst they may be first over the line and should be congratulated, the scale of their operations, at present, is a fraction of what HELD have been granted in Greece. CEL are also operating from a country with considerably higher costs.

Current mkt cap: £265M

HELD: c.£11M.

HELD still have work to do, but should, all being well, be rubber stamped and selling product at around the end of Q2.

Posted at 10/3/2023 12:57 by oakridge
I suspect Celadon will get its own thread in time.

I've researched this company (and others within the sector) well.

It sits right within the SPACE I'm interested in for 2023.

People looking in at CEL's rise should also look at freshly listed HELLENIC DYNAMICS (HELD). HELD are Medicinal Cannabis cultivators with one of the largest cultivation licenses granted anywhere in Europe. They will be growing out of a site, which is deemed strategically astute/significant, in northern Greece. They are the only pure-play cultivators (ie suppliers) listed on the LSE main mkt.

HELD are trading at a barely visible 0.085p a share (ie less than a tenth of a penny) but the first harvest is expected in late Q2 and they have recently reiterated more than adequate cash runway to get them to first sales (term sheets already signed into the German mkt).

Huge upside if they can prove they are operationally competent. I believe they will prove just that with a good BOD and key proven staff (eg Carl Haffner - ex Avida Global!) brought in to help make it all happen.

Celadon are interesting in that they have direct access into a key clinical trial. Their UK based growing facility will be phased, much like Hellenic's , but their capacity is, I think around 10% of Hellenic's total granted license....which will run at a staggering 54,000kg of dried THC dominant flowers a year (when fully maxed out in PIII). In other words, Hellenic have the potential to become one of the largest European based suppliers, coupled with the cheapest cost base (ie water, energy and labour) that come with being located in rural Greece.

This gives you some idea of the potential of Hellenic, should they get it right.

But any trial data coming out of companies like CEL will be important and a rising tide should lift all boats.

Interesting times for the space.

Celadon Pharmaceuticals share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |